Martin Ungerer is a physician and cardiologist. He studied at the University of Munich and spent an academic year in France. After a post-doctoral stay at the Max Planck Institute for Biochemistry/Gene Center, Martinsried, he completed his specialist training as an internist and cardiologist at the Klinikum rechts der Isar and German Heart Center of the TU Munich, where he also did his habilitation. From 2000 onwards, he founded biotech companies together with colleagues and managed them as Chief Scientific/Medical Officer and Managing Director: ProCorde GmbH until its merger with Trigen plc, London, Corimmun GmbH, which was sold to Janssen-CILAG/Johnson & Johnson in 2012, and advanceCOR GmbH. In these companies he was responsible for the translation of research projects from preclinical studies to clinical phase I and II studies in the fields of cardiovascular diseases and immunology. Martin Ungerer has also continuously been working in patient care on a part-time basis and is a professor of medicine at the University of Würzburg. He also works for the Translational Research Group (TRG) of the German Centre for Cardiovascular Research (DZHK), Berlin.